FDA approves pill which can prevent heart attack, stroke by reducing inflammation: How it works
The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This medication, previously for type 2 diabetes, now offers a needle-free option to reduce inflammation and oxidative stress, protecting heart and blood vessels. It also aids blood sugar and weight management, marking a significant advancement in preventative heart care.
The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This medication, previously for type 2 diabetes, now offers a needle-free option to reduce inflammation and oxidative stress, protecting heart and blood vessels. It also aids blood sugar and weight management, marking a significant advancement in preventative heart care.
